Parisian stent developer nets $22M in series B financing
Coronary stent developer Stentys has secured the second tranche of its Series B financing from Sofinnova Partners and Scottish Equity Partners -- closing an additional $4.2 million investment from new investor Crédit Agricole Private Equity -- bringing the total B round financing to more than $22 million.

The Paris-based Stentys was founded in 2006 to develop a new stent designed for treatment of acute MI and coronary artery bifurcations.

"Stentys has completed an initial 40 patient clinical trial demonstrating safety and efficacy of the stent," said Gonzague Issenmann, Stentys' CEO. "This second financing tranche of the Series B round will enable Stentys to obtain CE marking and begin European marketing of the first self-expanding stent platform for the treatment of MI."